Artivion (NYSE:AORT) Hits New 52-Week High at $21.90

Artivion, Inc. (NYSE:AORT - Get Free Report) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as $21.90 and last traded at $21.59, with a volume of 4555 shares changing hands. The stock had previously closed at $21.64.

Analyst Upgrades and Downgrades

AORT has been the subject of a number of research analyst reports. Stifel Nicolaus raised their target price on Artivion from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, February 16th. Needham & Company LLC reiterated a "buy" rating and set a $25.00 price objective on shares of Artivion in a research note on Monday.

Artivion Trading Down 0.0 %

The firm has a market capitalization of $891.16 million, a price-to-earnings ratio of -28.84 and a beta of 1.67. The company has a current ratio of 4.85, a quick ratio of 3.43 and a debt-to-equity ratio of 1.10. The company has a fifty day moving average price of $19.42 and a two-hundred day moving average price of $17.27.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings results on Thursday, February 15th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of ($0.13) by $0.24. The firm had revenue of $93.67 million for the quarter, compared to analyst estimates of $89.75 million. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. As a group, research analysts forecast that Artivion, Inc. will post 0.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Jean F. Holloway sold 3,527 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $18.86, for a total value of $66,519.22. Following the completion of the transaction, the senior vice president now owns 131,858 shares in the company, valued at $2,486,841.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Artivion news, SVP Jean F. Holloway sold 3,527 shares of the company's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $18.86, for a total value of $66,519.22. Following the completion of the transaction, the senior vice president now owns 131,858 shares in the company, valued at $2,486,841.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Marshall S. Stanton sold 2,183 shares of the company's stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total transaction of $44,511.37. Following the completion of the sale, the senior vice president now directly owns 83,296 shares of the company's stock, valued at $1,698,405.44. The disclosure for this sale can be found here. Insiders have sold a total of 149,952 shares of company stock valued at $2,891,627 over the last quarter. 6.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Money Concepts Capital Corp acquired a new stake in Artivion during the fourth quarter worth approximately $28,000. Tower Research Capital LLC TRC raised its stake in Artivion by 89.3% during the second quarter. Tower Research Capital LLC TRC now owns 1,677 shares of the company's stock worth $29,000 after purchasing an additional 791 shares during the period. GAMMA Investing LLC raised its stake in Artivion by 38.6% during the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company's stock worth $38,000 after purchasing an additional 505 shares during the period. Captrust Financial Advisors purchased a new position in Artivion during the second quarter worth approximately $39,000. Finally, State of Wyoming raised its stake in Artivion by 207.1% during the fourth quarter. State of Wyoming now owns 3,495 shares of the company's stock worth $42,000 after purchasing an additional 2,357 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.